HUYA Bioscience International expanded oncology pipeline includes combination with checkpoint inhibitor for solid tumors

San Diego, CA, USA – June 4, 2018 – HUYA Bioscience International (HUYA), the leader in accelerating global development of China’s pharmaceutical innovations, today announced it is at a key stage in the company’s development of HBI-8000, HUYA’s lead novel epigenetic drug with important immunomodulatory properties. HUYA is conducting a Phase 2 trial of HBI-8000 in the US, investigating efficacy and safety in combination with nivolumab for the treatment of solid tumors.

HUYA Bioscience International Establishes Strategic Partnership with Suzhou BioTOP

San Diego, CA, USA – July 10, 2017 – HUYA Bioscience International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced a strategic collaboration agreement with Suzhou BioTOP Technical Service Co., Ltd. (referred to as BioTOP). The collaboration will focus on promoting the development of biomedical innovations from companies and research organizations in Suzhou BioBay that help to meet the increasing demand to fill global pharmaceutical pipelines.

HUYA Bioscience International and CAS Innovation and Investment Company Establish Strategic Collaboration

San Diego, CA, USA – January 18, 2017HUYA Bioscience International (HUYA), the leader in accelerating the global development of China’s pharmaceutical innovations, announced today a strategic collaboration agreement with the Chinese Academy of Sciences Innovation and Investment Company (referred to as CAS Innovation). The collaboration will focus on developing and commercializing biomedical innovations discovered by leading scientists at CAS to meet the medical needs of patients around the world.

HUYA Bioscience International Sponsors 12th Annual Scrip Awards ‘Best New Drug’ Category

San Diego, CA, USA – December 14, 2016 – For the second straight year, HUYA Bioscience International (HUYA) was a proud sponsor of the Best New Drug category at the Annual Scrip Awards.

HUYA Bioscience International Dr. Mireille Gillings Named Pharma Executive of the Year at the BioPharma Industry Awards 2016

Recognized for Visionary Leadership Within Asia’s Pharmaceutical Industry

San Diego, CA, USA – March 24, 2016HUYA Bioscience International (HUYA) Founder and Executive Chair Mireille Gillings, Ph.D., has been named Pharma Executive of the Year at the BioPharma Industry Awards 2016. Presented in conjunction with the 9th BioPharma Asia Convention 2016.

HUYA Bioscience International Celebrates 10 Years in China

Biopharma Company with Joint HQ in Shanghai & San Diego Commemorates a Decade of Innovation

Shanghai, China – March 22, 2016HUYA Bioscience International (HUYA) celebrated the 10th anniversary of the opening of its first offices in China with a gala dinner at the ‘M on the Bund’ restaurant in Puxi, Shanghai.

HUYA Bioscience International Acquires Exclusive Rights to Immuno-Oncology Products from Fudan University

Inhibitors of indoleamine 2,3-dioxygenase to be Developed for Oncology Therapy

San Diego, CA, USA – March 15, 2016HUYA Bioscience International (HUYA), the leader in accelerating global development of China’s pharmaceutical innovations, today announced it has signed an exclusive license with Fudan University for the ex-China rights to a series of novel immuno-oncology drug candidates discovered by Fudan researchers.

HUYA Bioscience International Grants an Exclusive License for HBI-8000 in Japan and Other Asian Countries to Eisai

Eisai to commercialize HUYA’s Product in Lymphoma and Develop New Indications in Solid Tumors

San Diego, CA, USA – February 1, 2016HUYA Bioscience International (HUYA) President, CEO, Executive Chairman & Founder Dr. Mireille Gillings announced that Eisai Co., Ltd. has acquired from HUYA an exclusive license agreement for HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore.

HUYA Bioscience International Announces Orphan Drug Designation for HBI-8000 in Japan

HBI-8000 granted orphan drug designation for peripheral T-cell lymphoma in Japan

San Diego, CA, USA – December 22, 2015HUYA Bioscience International (HUYA), Founder, CEO & Executive Chair, Dr. Mireille Gillings today announced that the Ministry of Health, Labour and Welfare (MHLW) granted HBI-8000 orphan drug designation in Japan for peripheral T-cell lymphoma (PTCL).

HUYA Bioscience International Sponsors ‘Best New Drug’ Category at SCRIP Awards

Supports Prestigious Award Recognizing Excellence in Pharmaceutical Development

San Diego, CA, USA – December 3, 2015HUYA Bioscience International (HUYA) was a proud sponsor of the ‘Best New Drug’ category at the 11th Annual SCRIP Awards. Dr. Mireille Gillings was a finalist for ‘Executive of the Year’ and HUYA was a finalist for ‘Best Company in an Emerging Market’.

HUYA Bioscience International Expands into South Korea

Seoul Office Will Head Operations to Develop Korean Biopharmaceutical Innovation

Seoul, Korea – December 2, 2015HUYA Bioscience International (HUYA), the global leader in accelerating drug discovery and development of biopharma innovation originating in China, recently opened its first Corporate office in Korea. This continues to build on HUYA’s overall strategy to be the partner-of-choice for innovative pharmaceutical companies in emerging centers of excellence worldwide.

HUYA Bioscience International Announces a Strategic Alliance with the Korea Drug Development Fund

San Diego, CA, USA – November 30, 2015 –HUYA Bioscience International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced it has signed a Memorandum of Understanding with the Korea Drug Development Fund (KDDF) to foster collaboration between KDDF and HUYA with the ultimate goal of advancing Korean development and commercialization of healthcare products for the global market.

HUYA Bioscience International Celebrates its 10th Anniversary

San Diego Biotech Firm Commemorates a Decade of Innovation

San Diego, CA, USA – November 16, 2015 –HUYA Bioscience International (HUYA) just celebrated its 10th anniversary of the company’s founding with a black tie gala event on November 13 at the U.S. Grant Hotel in San Diego. The company honored its 10 years of international pharmaceutical innovation and development with live entertainment and video greetings from colleagues and key opinion leaders in Japan and China.

HUYA Bioscience International and TechCode Gu’an Lifesciences Park Establish Strategic Collaboration

San Diego, CA, USA – November 9, 2015 –HUYA Bioscience International, the leader in accelerating the global development of China’s pharmaceutical innovations, today announced a strategic collaboration agreement with TechCode Gu’an Life Sciences Park (referred to as TechCode Gu’an Park). The collaboration will focus on promoting the development of biomedical innovations from companies located in the park that could help meet the growing demand to fill global pharmaceutical pipelines.

HUYA Bioscience International Further Expands Executive Team

Appoints Gloria Tsi-Yie Lee, M.D., Ph.D., as Chief Medical Officer

San Diego, CA, USA – September 15, 2015 –HUYA Bioscience International (HUYA) today announced the expansion of its Executive Team with the appointment of Gloria Tsi-Yie Lee, M.D., Ph.D., as Chief Medical Officer.

HUYA Bioscience International Announces Epigenetic Breast Cancer Program

Expansion marked by clinical development for multiple HER2 subtypes of breast cancer

San Diego, CA, USA – September 3, 2015 –HUYA Bioscience International (HUYA) today announced expanding clinical trials with its lead cancer drug, HBI-8000, starting with a Phase 1 combination trial in support of a breast cancer program to be conducted in the United States.

HUYA Bioscience International Sponsors Japan Society of HTLV-1 Annual Meeting

San Diego, CA, USA – August 27, 2015 –HUYA Bioscience International (HUYA) today announced the sponsorship of the second annual meeting of the Japan Society of HTLV-1, held this week at the University of Tokyo Medical Science Institute Auditorium.

HUYA Bioscience International CEO, Mireille Gillings, Ph.D., Named As Gold Award Winner In 2015 American Business Awards

13th annual Stevie® Awards presented on June 22 in Chicago

San Diego, CA, USA – June 23, 2015 –HUYA Bioscience International CEO and Executive Chairman, Mireille Gillings, Ph.D., has been named a Gold Stevie® Award Winner in the ‘Woman of the Year, Health Products and Services & Pharmaceuticals’ category in The 2015 American Business Awards.

HUYA Bioscience International Wins Bronze Stevie® Award In 2015 Asia-Pacific Stevie Awards

Winners to be Celebrated at Gala Banquet on 5 June in Shanghai, China

San Diego, CA, USA & Shanghai, China – May 26, 2015 –HUYA Bioscience International has been named the winner of a bronze Stevie® Award in the Health Products & Services and Pharmaceuticals category in the second annual Asia-Pacific Stevie Awards.

HUYA Bioscience International Completes First Cohort In Phase 1 Clinical Trial Of HBI-8000 In Japan

Second cohort underway in non-Hodgkin’s lymphoma patients

San Diego, CA, USA – March 19, 2015 –HUYA Bioscience International (HUYA) has completed the first cohort in a Phase 1 clinical trial in Japan of its cancer drug HBI-8000, a novel oral histone deacetylase (HDAC) inhibitor. This follows acceptance by the Pharmaceutical and Medical Devices Agency (PMDA) of the company’s accelerated development strategy in Japan.

HUYA Bioscience International Announces Regulatory Approval Of Chidamide, The First Selective HDAC Inhibitor In China

HUYA holds exclusive rights to chidamide as HBI-8000 ex-China

San Diego, CA, USA – January 12, 2015 –HUYA Bioscience International (HUYA) announced today that Shenzhen Chipscreen Biosciences (Chipscreen) has obtained marketing approval from the Chinese FDA for the world’s first oral HDAC inhibitor, chidamide, for the treatment of relapsed or refractory peripheral T-cell lymphoma. 

HUYA Bioscience International Is The First To Leverage Tripartite Cooperation

PMDA accepts accelerated development strategy for HBI-8000, a novel cancer drug

San Diego, CA, USA – January 8, 2015 –HUYA Bioscience International (HUYA) announced today that the Pharmaceutical and Medical Devices Agency (PMDA) has accepted its accelerated development strategy for the novel cancer drug HBI-8000. HUYA is developing HBI-8000 for the treatment of adult T-cell leukemia/lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) in Japan.

HUYA Bioscience International Establishes Alliance With China Wuqing Development Area

San Diego, CA, USA – December 18, 2014 – HUYA Bioscience International, a leader in accelerating the global development of China’s pharmaceutical innovations, today announced a strategic collaboration agreement with China Wuqing Development Area, a state-level economic and technological development area located between Beijing and Tianjin. The collaboration will focus on promoting biomedical innovations from companies located in the Area.

HUYA Bioscience International And TIPR Announce Joint Venture To Develop Medical Innovation For Global Markets

San Diego, CA, USA – September 15, 2014 – HUYA Bioscience International (HUYA), a leader in accelerating the global development of China’s pharmaceutical innovations, today announced a joint venture with Tianjin Institute of Pharmaceutical Research (TIPR) to develop medical technologies and therapies, originating in both China and the western world, for global markets.

HUYA Bioscience International Announces Partnership with Changzhou Center for Biotech Development

San Diego, CA, USA – August 18, 2014 — HUYA Bioscience International, a leader in accelerating the global development of China’s pharmaceutical innovations, today announced a strategic partnership with the Changzhou Center for Biotech Development (CZCBD). This partnership will focus on advancing the worldwide potential of innovations from bio-pharmaceutical companies located in Changzhou that could meet critical global pharmaceutical pipeline needs.

HUYA Bioscience Announces Partnership With Shanghai Zhangjiang Biotech Pharmaceutical Base

San Diego, CA, USA – March 6, 2013 — HUYA Bioscience International announced today a collaborative partnership with Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co., Ltd. and Shanghai Pharma Engine Co. Ltd. (collectively, “Zhangjiang Biotech Pharmaceutical Base”). HUYA is an international leader in accelerating the global development of China’s pharmaceutical innovations.

HUYA Bioscience Announces New Partnership With Tianjin Research Center Of Basic Medical Sciences

San Diego, CA, USA – August 20, 2012 — HUYA Bioscience International announced today a strategic partnership with one of China’s leading research organizations, Tianjin Research Center of Basic Medical Sciences (TJRCBMS). HUYA is an international leader in accelerating the global development of China’s pharmaceutical innovations. Their new partnership with TJRCBMS will focus on innovations coming out of this newly formed institution that could meet critical global pharmaceutical pipeline needs.

HUYA Bioscience Announces New Partnership With A High Profile Pharmaceutical Lab At Shanghai’s Prestigious Fudan University

San Diego, CA, USA – March 20, 2012 — HUYA Bioscience International announced today a critical strategic partnership with one of China’s preeminent pharmacological researchers, Prof. Deyong Ye of Fudan University’s School of Pharmacy. HUYA is an international leader in supporting the global development of China’s pharmaceutical innovations. Their new partnership with Fudan University will focus on specific innovations coming out of Prof.

HUYA Bioscience International Announces Strategic Partnership With The Tianjin Institute Of Pharmaceutical Research

San Diego, CA, USA – January 18, 2012 — HUYA Bioscience International today announced a strategic partnership agreement with the Tianjin Institute of Pharmaceutical Research (TIPR). HUYA is a leader in globalizing China’s biopharmaceutical innovations and TIPR is one of the leading pharmaceutical research institutes in China. The collaborative agreement will combine both parties‘ strengths in promoting the advancement of China’s drug innovations.

HUYA Bioscience International Builds Long-Term Relationship With Shenzhen Polytechnic School Of Applied Chemistry And Biotechnology

San Diego, CA, USA – November 8, 2011 — HUYA Bioscience International, a leader in globalizing China’s pharmaceutical innovations, today announced a strategic partnership with the Shenzhen Polytechnic School of Applied Chemistry and Biotechnology (SPSACBT). The alliance with HUYA will assist the school in accelerating the development of novel drugs, discovered from research laboratories within the school, to international standards.

HUYA Bioscience International And Tianjin International Joint Academy Of Biotechnology And Medicine Form Alliance

San Diego, CA, USA – October 18, 2011 — HUYA Bioscience International, a leader in globalizing China’s biopharmaceutical innovations, today announced a strategic alliance with the Tianjin International Joint Academy of Biotechnology and Medicine (TJAB). The alliance will unite the strength and resources of both parties to accelerate the development of China’s biomedical innovation and industrialization.

HUYA Bioscience International Forms Alliance With Zhejiang Chinese Medical University Life Science College

San Diego, CA, USA – September 8, 2011 — HUYA Bioscience International, a leader in globalizing China’s pharmaceutical innovations, today announced a strategic partnership with the Zhejiang Chinese Medical University Life Science College. The collaboration agreement will accelerate the global drug development of China’s novel Traditional Chinese Medicines (TCM).

HUYA Bioscience International Engages In Partnership With Liaoning (Benxi) Bio-Pharmaceutical Industry Base

San Diego, CA, USA – July 8, 2011 — HUYA Bioscience International, a leader in globalizing China’s biopharmaceutical innovations, today announced a strategic partnership with the Liaoning (Benxi) Bio-Pharmaceutical Industry Base. The collaboration agreement will combine both parties’ strength in aiding the advancement of China’s drug innovation platform.

HUYA Bioscience And Wuhan Biolake Form Alliance To Help Accelerate China’s Bio-Industry Development

San Diego, CA, USA – March 8, 2011 — HUYA Bioscience International, a leader in globalizing China’s pharmaceutical innovations, today announced a strategic alliance with Wuhan National Bio-industry Base, also known as Biolake. The alliance is expected to combine both parties’ resources to accelerate the development of pharmaceutical discoveries from China.

HUYA Bioscience And Quintiles Announce Partnership For Phase I Development Of New Cancer Therapy

China-sourced cancer drug enters U.S. clinical trials

San Diego, CA & Research Triangle Park, N.C. – September 28, 2010 — HUYA Bioscience International (HUYA), the leader in U.S.-China pharmaceutical co-development, and Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced an agreement to co- develop a new cancer drug, HBI-8000, sourced in China by HUYA.

HUYA Biosciences Establishes Strategic Partnership With Sun Yat-Sen University’s School Of Pharmaceutical Sciences

San Diego, CA, USA – August 30, 2010 — HUYA Bioscience International, a company at the forefront of globalizing China’s biopharmaceutical innovations, today announced a strategic partnership with the School of Pharmaceutical Sciences at Sun Yat-sen University (SYSU). The collaborative agreement expands HUYA’s foothold in Southern China, aiming to accelerate the development of novel drugs arising from the school’s research efforts.

HUYA Bioscience International And China Medical City Forge Alliance To Help Develop China’s Pharmaceutical Industry

San Diego, CA, USA – June 28, 2010 — HUYA Bioscience International, a leader in globalizing China’s pharmaceutical innovations, today announced a strategic partnership with the Taizhou National Medical Hi-tech Development Zone, also known as “China Medical City” (CMC). The alliance will combine both parties’ strengths in pharmaceutical product R&D and commercialization in order to promote China’s pharmaceutical-biotech industry to the world- class level.

HUYA Bioscience International Strengthens R&D Leadership In Traditional Chinese Medicine With The School Of Chinese Materia Medica, Beijing University Of Chinese Medicine

San Diego, CA, USA – May 28, 2010 — HUYA Bioscience International, a leader in globalizing China’s biopharmaceutical innovation, today announced a strategic partnership with the School of Chinese Materia Medica of the Beijing University of Chinese Medicine (BUCM). As one of a series of collaborations that HUYA has established with China’s leading research and development institutions, the agreement demonstrates HUYA’s visionary commitment to enabling and accelerating the global development and commercialization of novel biopharmaceutical products originating in China.

HUYA Bioscience International Establishes Strategic Partnership With School Of Medicine And Pharmacy, Ocean University Of China

San Diego, CA – November 8, 2009 — HUYA Bioscience International, a leader in globalizing China’s biopharmaceutical innovation, today announced a strategic partnership with the School of Medicine and Pharmacy, Ocean University of China. The agreement is another in a series of collaborations that HUYA has established with China’s leading research and development institutions to enable and accelerate the global development and commercialization of novel biopharmaceutical product opportunities originating in China.

Solvay Pharmaceuticals Announces Strategic Partnership With HUYA To Access New Drug Candidates From China

Brussels – May 18, 2009 — Solvay Pharmaceuticals announces it has signed an agreement with HUYA Bioscience International, a company specialized in enabling and accelerating global co- development of novel biopharmaceutical product opportunities originating in China.

Through this agreement, Solvay Pharmaceuticals will gain access to HUYA’s comprehensive Chinese molecule portfolio, focusing specifically on compounds in the cardiovascular area.

HUYA Bioscience Announces Strategic Alliance With Abbott On Drug And Biomarker Development Candidates From China

Collaboration will leverage HUYA’s growing Chinese bioscience network

San Diego, CA – April 21, 2009 — HUYA Bioscience International, a leader in US/China pharmaceutical co-development, today announced an agreement with Abbott to identify and pursue proprietary preclinical and clinical drug candidates that originate in China.

Abbott will gain access to HUYA’s growing Chinese bioscience network comprising premier companies, universities, government research institutions and bioparks throughout the country.

HUYA Bioscience Int’l Announces Collaboration Agreement With The Beijing Institute Of Materia Medica, Chinese Academy Of Medical Sciences And Peking Union Medical College

HUYA to Collaborate on Pre-clinical and Clinical Studies for Chinese Drugs

San Diego, CA – February 18, 2009 — HUYA Bioscience International, the leader in US/China pharmaceutical co-development, today announced a partnership agreement with the Beijing Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College (collectively – The Beijing Institute of Materia Medica, BIMM).

HUYA Bioscience Announces Agreement To Provide Schering- Plough With Drug Development Candidates From China

Collaboration will leverage HUYA’s growing Chinese bioscience network

San Diego, CA, USA – December 15, 2008 — HUYA Bioscience International, a leader in US/China pharmaceutical co-development, today announced an agreement with Schering-Plough Corporation’s subsidiary, N.V. Organon. Schering-Plough has selected HUYA to identify and present to Schering-Plough on an exclusive basis proprietary lead, preclinical and clinical drug candidates in specific therapeutic areas that originate in China.

HUYA Bioscience Int’l Announces First Pre-Ind Outcome For A Development Stage Compound Sourced From China – Hbi-8000, Promising New Cancer Compound

FDA feedback validates HUYA’s Integrated Co-Development Model for China-sourced Drug Candidates

San Diego, CA, USA – April 14, 2008 — HUYA Bioscience International (HUYA), the leader in U.S./China pharmaceutical co-development, today announced the outcome of the first pre-IND (Investigational New Drug) consultation with the U.S. FDA for a development-stage compound sourced from China.

HUYA Bioscience Int’l Announces Clinical Trial Milestones In China For Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile

Progress validates HUYA’s innovative U.S./China pharmaceutical co-development model

San Francisco, CA, USA, IBC Conference – March 3, 2008 — HUYA Biosciences International (HUYA), the leader in U.S./China pharmaceutical co-development, today announced the completion of three Phase I clinical trial protocols in China of a promising anti-arrhythmic compound, HBI-3000 (Sulcardine sulphate). The data from the trials support a desirable safety profile at dose levels displaying indications of pharmacologic activity.

HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound From The Shanghai Institute Of Materia Medica

San Diego, USA and Shanghai, China – October 2, 2007 — HUYA Bioscience International (HUYA), a rapidly expanding biopharmaceutical company focused on the development of key disease-fighting drugs sourced from China, announced today that it has licensed a novel clinical stage anti-arrhythmic compound from the prestigious Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences.

HUYA Bioscience International And Chipscreen Biosciences Initiate A Phase I Clinical Cancer Trial

San Diego, USA and Shenzhenm China – May 24, 2007 — HUYA Bioscience International, LLC and Chipscreen Biosciences Ltd. announced today that a Phase I clinical trial has been initiated in China with the compound Chidamide (CS055) /HBI- 8000, an investigational cancer compound. HUYA holds exclusive rights to the compound (HBI-8000) worldwide outside of China, while Chipscreen maintains rights in China.

HUYA Bioscience Licenses Chidamide Cancer Compound from Chipscreen Biosciences

San Diego USA and Shenzhen, China – March 6, 2007 — HUYA Bioscience International, LLC, announced today that it has exclusively licensed worldwide rights outside China to the cancer compound chidamide from Shenzhen Chipscreen Biosciences Ltd.
Chidamide, is an investigational cancer compound currently approved to initiate a Phase I clinical trial in China.

Organon Partners With HUYA To Identify And Develop Chinese Biopharmaceuticals

Collaboration looks for opportunities to expand the Organon biotech research programs and facilitate links with China’s biotech industry

Oss, The Netherlands and San Diego, USA – January 9, 2007 — Organon, the human healthcare business of Akzo Nobel (Nasdaq: AKZOY), announced today that it has signed a collaboration agreement with HUYA Bioscience International, LLC, (HUYA) to search for new, proprietary biopharmaceuticals or pharmaceutical compounds.